Effect of Periodontal Treatment on Metabolic Control in Patients with Type-2 Diabetes Mellitus Treated in the Cardiovascular Healt Program

Launched by UNIVERSITY OF CHILE · Mar 19, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at how treating gum disease, known as periodontitis, can help improve blood sugar control in adults who have type 2 diabetes. Researchers want to see if dental treatment can reduce a specific marker in the blood called glycated hemoglobin (or HbA1c), which helps show how well diabetes is being managed over time. Participants will receive non-surgical dental treatment and complete a survey about their quality of life. The study will follow participants for one year to see how their health changes.

To join the trial, you need to be an adult between the ages of 65 and 74, have type 2 diabetes with a recent HbA1c level of 7% or higher, and be diagnosed with periodontitis. However, if you've had gum treatment in the last year, are pregnant or breastfeeding, or have taken certain medications recently, you won't be eligible. This trial is currently recruiting participants, and it offers a chance to explore how improving dental health may positively impact diabetes management.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1a. Patients enrolled in the PSCV with a diagnosis of type 2 diabetes mellitus and who, in turn, have a glycated hemoglobin ≥ 7% (during the last 6 months).
• • 1b. Patients with a diagnosis of periodontitis (≥ 2 non-adjacent teeth with detectable clinical interproximal attachment loss or, attachment loss ≥ 3mm with depth to probing ≥ 3mm on free faces of ≥ 2 teeth, where the attachment loss was not attributed to non-periodontal causes (Papapanou et al., 2018)).
• Exclusion Criteria:
• • 2a. Patients who have received periodontal treatment during the last year.
• • 2b. Pregnancy/lactation, because they are under treatment under the Explicit Health Guarantee "Oral and Integral Health of Pregnant Women".
• • 2c. Therapy with antibiotics and/or non-steroidal anti-inflammatory drugs (NSAIDs) in the last 6 months prior to the study.